Should women over 40 use topical or injectable GHK-Cu?

The short answer

Evidence tier: 3 — small, older, partly unpublished human cosmetic studies for topical use; no human data for injection.

For women over 40, the only route with any human evidence is topical GHK-Cu. That evidence is thin: a handful of small cosmetic studies, mostly from 1998–2005, several of which were never published as full peer-reviewed papers.

Injectable GHK-Cu has no published human trials at all, for skin or anything else. In the US it sits in a regulatory gap after FDA removed it from the compounding Category 2 list in April 2026. That removal did not make it legal to compound. Advisory committee review is expected before the end of February 2027.

Copper load is a key safety question, alongside sterility and immunogenicity for injections. Topical use delivers small amounts. Injecting bypasses the gut, which normally controls how much copper the body absorbs. People with Wilson's disease should avoid copper peptides by any route unless their specialist advises otherwise.

The key points:

• Topical copper peptide creams improved photoaged skin in small 12-week studies of women, but the best-known trials exist only as unpublished 2002 reports.
• A 2026 systematic evidence map found the clinical evidence "sparse" and concluded GHK-Cu remains "promising but unproven".
• No randomised trial has tested injected GHK-Cu in humans. FDA lists immunogenicity as a concern for compounded injectable GHK-Cu.
• On a label, GHK-Cu appears as Copper Tripeptide-1. "Palmitoyl tripeptide-1" is a different, copper-free peptide.
• A true GHK-Cu solution is blue. A colour shift to green or brown can mean the complex has broken down.

Why is everyone suddenly searching for GHK-Cu?

Evidence tier: 5 — search-trend data and social media, not clinical evidence.

Interest in GHK-Cu took off in 2026. The trend tracker Exploding Topics shows 10-year search growth of about 3,700% for "ghk cu" (Exploding Topics). Two things drove it: copper peptide skincare going viral, and the April 2026 FDA notice that put injectable peptides in the news.

Popularity tells you about marketing, not results. The rest of this article separates what has been measured in women from what has only been claimed.

Why is skin after 40 a reasonable target?

Evidence tier: 2 — consistent human observational data on post-menopausal collagen loss.

After menopause, skin collagen and skin thickness fall by about 1–2% per year, in step with bone loss (Brincat 1987). Lower estrogen is the main driver (Calleja-Agius & Brincat 2012).

In the lab, GHK-Cu stimulates collagen production by fibroblasts (Maquart 1988), so the idea makes biological sense. Whether a cream reproduces that effect in a 55-year-old face is a separate question. We cover the menopause side in detail in our menopause skin-thinning guide. This article sticks to the route question.

What does the human evidence for topical GHK-Cu show?

Evidence tier: 3 — small controlled studies, mostly unpublished or underpowered, with heavy involvement from developers of the ingredient.

These are the human studies most often quoted, and what each one is:

• Abdulghani et al., 1998. 20 volunteers applied creams to their thighs for one month, with biopsies before and after. Collagen production rose in 7 of 10 people using the copper peptide cream, compared with 4 of 10 on tretinoin and 5 of 10 on vitamin C or melatonin (Mount Sinai abstract; DOI00011-4)). This is a pilot study of thigh skin, not the face, and each arm had only 10 people.
• Leyden et al., 2002 (facial cream). 71 women with mild-to-advanced photoaging used the cream for 12 weeks. Reported results were better laxity, clarity and skin density, and fewer fine lines. This was presented at the American Academy of Dermatology meeting but never published as a full paper.
• Leyden et al., 2002 (eye cream). 41 women with photodamage used it around the eyes for 12 weeks. It reportedly beat both placebo and a vitamin K eye cream on lines, wrinkles and skin density. This is cited only as a 2002 University of Pennsylvania report and was never published.
• Finkley/Appa, 2005. 67 women aged 50–59 applied a cream twice daily for 12 weeks. Laxity, wrinkles and mottled pigmentation improved. This appeared in a textbook chapter, not a peer-reviewed journal.
• Miller et al., 2006. A randomised trial of copper peptide products after CO2 laser resurfacing in 13 people who completed it. Objective measures showed no difference. Only patient satisfaction was higher (PMID 16847171).

Most of what we know about the Leyden and Finkley studies comes from reviews written by GHK-Cu's discoverer (Pickart 2015; Pickart & Margolina 2018). A 2026 systematic review pointed out that about 35% of the GHK-Cu primary literature involves the same small group, which limits how independent the evidence base is (Najafi 2026).

A separate 2026 evidence map put it bluntly. The clinical evidence "remains sparse", historical cosmetic reports are "small or incompletely characterized", and none of the studies measured how much intact GHK-Cu reached the skin (Mateescu 2026). A 2025 review of topical GHK as an anti-wrinkle ingredient also noted "a surprising absence of clinical studies" (Mortazavi 2025).

For comparison, two other cosmetic peptides have published peer-reviewed data in women. Palmitoyl pentapeptide (the original Matrixyl) reduced wrinkles in a 12-week split-face trial of 93 women aged 35–55 (Robinson 2005). Argireline at 10% reduced wrinkle depth by up to 30% over 30 days in a small study (Blanes-Mira 2002). These studies are also small, but at least they appear in full in journals.

Is there any human evidence for injectable GHK-Cu?

Evidence tier: 5 — no published human trials; claims come from clinics, vendors and forums.

No. We found no published randomised or controlled trial of injected GHK-Cu in humans for skin, hair, or "systemic anti-ageing". The 2026 evidence map says injectable products carry "the full parenteral burden": sterility, endotoxin, particles, systemic copper exposure and immunogenicity all need testing. It also states that no validated human safety limit for GHK-Cu exposure exists (Mateescu 2026).

The injection claims come from extrapolation: if a cream works a little, an injection should work more. Nobody has tested that. Animal wound-chamber injections do show collagen effects, but those were rats with surgical wounds, not intact ageing human skin.

What is the FDA and EU status in 2026?

Evidence tier: 1 — regulator documents and legal analyses of them.

United States

• On 15 April 2026, FDA said it would remove injectable GHK-Cu from Category 2 of its bulk drug substances list because the nomination was withdrawn. In the same notice it removed non-injectable GHK-Cu from Category 1 (Frier Levitt).
• FDA's own page now lists injectable GHK-Cu under "nominated but withdrawn" and notes that "compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity" (FDA).
• Leaving Category 2 does not make a substance compoundable. Interim enforcement discretion covers only Category 1 substances, so neither form of GHK-Cu now falls under it (Frier Levitt).
• Injectable GHK-Cu is slated for Pharmacy Compounding Advisory Committee (PCAC) consultation before the end of February 2027. At the July 2026 meeting, the committee narrowly backed six of seven other peptides and voted against emideltide (DSIP). Those votes are non-binding (AJMC).
• Over-the-counter cosmetic creams containing copper tripeptide-1 are a different category. These rules apply to pharmacy-compounded drugs, not to cosmetics.

EU and UK

• Copper Tripeptide-1 is listed in the EU cosmetic ingredient database (CosIng) as a skin-conditioning ingredient (CosIng entry).
• We found no EMA- or MHRA-authorised GHK-Cu medicine. Injectable vials sold online are typically labelled "research use only", which means no regulator has assessed them for human use.

See are peptides legal in 2026 for the wider picture.

What are the safety risks of each route?

Evidence tier: 4 — mechanistic reasoning, guideline data on copper, and community reports for injection-site effects.

Topical

• Irritation and occasional redness are the usual complaints.
• Some copper does get through the skin. In lab tests on human skin, some copper from a 0.68% copper tripeptide solution passed through and some stayed in the skin as a depot (Hostynek 2011).
• Homemade serums add contamination and dosing errors. See our DIY copper peptide serum safety article.

Injectable

• Burning and stinging at the injection site are the most common user reports. These are community reports, not trial data. We cover them in GHK-Cu injection burn and sting.
• Copper load. Normally the gut controls how much dietary copper gets absorbed. An injection skips that step. The adult tolerable upper intake for copper from all sources is 10,000 mcg per day (NIH ODS). Nobody has measured how injected GHK-Cu adds to total body copper over months.
• Immunogenicity, sterility and purity. These are FDA's stated concerns, and the reason unregulated vials carry extra risk.

Wilson's disease

Wilson's disease is an inherited disorder in which the body cannot clear copper, so it builds up in the liver and brain (EASL-ERN 2025; AASLD summary 2023). Anyone with Wilson's disease, or unexplained liver disease or copper abnormalities, should treat copper peptides as off-limits until a physician has reviewed them. Our Wilson's disease contraindication article explains why.

How do topical and injectable GHK-Cu compare?

Evidence tier: 3 — summary of the sections above.

How do you read a GHK-Cu label?

Evidence tier: 4 — ingredient nomenclature and supplier technical data.

Ingredient names

• Copper Tripeptide-1 is the official cosmetic (INCI) name for GHK-Cu.
• Palmitoyl Tripeptide-1 is GHK with a fatty-acid tail and no copper. It is one of the two peptides in Matrixyl 3000, alongside palmitoyl tetrapeptide-7. It is not GHK-Cu.

Concentration claims

• "1% copper peptide" often means 1% of a supplier's raw-material solution, not 1% pure GHK-Cu. One supplier's raw material contains 0.1% active peptide (1,000 ppm) and is meant to be used at 0.001–0.1% of the finished product (Avena Lab technical sheet).
• If a brand won't say whether its percentage refers to the active peptide or the raw material, you can't compare products.

The blue colour

• GHK-Cu in solution is blue.
• The complex is most stable at pH 5–7. EDTA, a common preservative booster, can pull the copper out and turn the solution green (Avena Lab).
• Under alkaline and oxidising conditions, GHK-Cu breaks down into fragments that include histidine (Badenhorst 2016).
• A "copper peptide" product with no colour, or one that has turned green or brown, may contain little intact complex.
• Suppliers advise against combining GHK-Cu with pure vitamin C (ascorbic acid) or strong acids in the same formula.

Limitations of the evidence

Evidence tier: 3 — summary of the evidence gaps above.

• The key topical trials (Leyden 2002, Finkley 2005) never appeared as full peer-reviewed papers and are known mainly through reviews by the ingredient's developers.
• The human studies are small (71 women at most) and short, with no long-term data.
• About a third of the primary literature comes from one small group, so independent replication is limited.
• No study measured how much intact GHK-Cu reached the skin.
• Injectable GHK-Cu has no published human trials and no validated safety limit; the injection data come from rats with surgical wounds.

The bottom line

If a woman over 40 wants to try GHK-Cu, topical products are the only route with any human data, and that data is weak. Injectable GHK-Cu is untested in humans, outside any approved pathway in the US, EU and UK, and adds copper and sterility risks without any proven extra benefit. Anyone with liver disease or a copper disorder should talk to a physician before using either form.

Related on this site

• Menopause skin thinning: what peptides can and can't do
• GHK-Cu vs tretinoin for skin density
• GHK-Cu injection burn and sting
• Wilson's disease and GHK-Cu
• DIY copper peptide serum safety
• Peptides for women: the 2026 cornerstone

References

• Abdulghani AA et al. Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin. Disease Management and Clinical Outcomes 1998 — 20-person thigh-biopsy pilot; not indexed in PubMed. DOI 10.1016/S1088-3371(98)00011-400011-4)
• Leyden JJ et al. Skin care benefits of copper peptide containing facial cream / eye creams. AAD 60th Annual Meeting (facial cream) / University of Pennsylvania report (eye cream) 2002 — unpublished; described in Pickart 2015 and Mateescu 2026.
• Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006 — randomised, 13 completers; no objective benefit. PMID 16847171
• Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015 — narrative review summarising the Leyden and Finkley studies. PMID 26236730
• Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018 — review by the ingredient's developers. PMID 29986520
• Mateescu DM et al. GHK-Cu as a bioactive metallopeptide and drug-delivery cargo. Pharmaceutics 2026 — systematic evidence map; clinical evidence sparse; injectable safety gaps. PMID 42797253
• Najafi N et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery. Arch Intern Med Res 2026 — notes concentration of authorship in the evidence base. PMID 42787770
• Mortazavi SM et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. Bioimpacts 2025 — finds few clinical studies. PMID 39963574
• Maquart FX et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex GHK-Cu2+. FEBS Lett 1988 — in vitro. PMID 3169264
• Brincat M et al. A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal woman. Obstet Gynecol 1987 — 1–2% yearly decline. PMID 3120067
• Calleja-Agius J, Brincat M. The effect of menopause on the skin and other connective tissues. Gynecol Endocrinol 2012 — review. PMID 21970508
• Robinson LR et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci 2005 — 93 women, split-face RCT. PMID 18492182
• Blanes-Mira C et al. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci 2002 — small human study plus mechanism. PMID 18498523
• Hostynek JJ et al. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflamm Res 2011 — in vitro skin permeation. PMID 20721598
• Badenhorst T et al. Physicochemical characterization of native GHK tripeptide for wound healing and anti-aging. Pharm Dev Technol 2016 — stability and degradation. PMID 25384620
• European Association for the Study of the Liver. EASL-ERN Clinical Practice Guidelines on Wilson's disease. J Hepatol 2025 — guideline. PMID 40089450
• Alkhouri N et al. Wilson disease: a summary of the updated AASLD Practice Guidance. Hepatol Commun 2023 — guideline summary. PMID 37184530
• US FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. 2026 — injectable GHK-Cu listed as withdrawn; immunogenicity note. fda.gov
• Frier Levitt. FDA to remove 12 popular peptides from the Category 2 list. 2026 — legal analysis of the 15 April 2026 notice. frierlevitt.com
• NIH Office of Dietary Supplements. Copper fact sheet for consumers. — RDA and upper limit. ods.od.nih.gov